Ohio State Navbar

Our Team

Terence Williams, MD, PhD




Associate Professor, Radiation Oncology
Dr. Williams Lab Website








  • 2003: American Association of Cancer Research (AACR) Avon Foundation Scholar-in-Training Award
  • 2005: American Society of Radiation Oncology (ASTRO) Translational Symposium Travel Grant Award
  • 2008: American Board of Radiology (ABR) B. Leonard Holman Research Pathway
  • 2009: ASTRO Translational Symposium Travel Grant Award
  • 2010: American Society of Clinical Oncology (ASCO) Merit Award
  • 2010: Cancer Education Consortium (CEC) Molecular & Translational Oncology Workshop Fellow
  • 2010: Radiological Society of North America (RSNA) Research Resident Grant
  • 2011: AACR Molecular Biology in Clinical Oncology Workshop Trainee
  • 2011: RSNA Roentgen Resident/Fellow Research Award
  • 2013: ASCO/AACR Methods in Clinical Cancer Research Workshop Trainee
  • 2013: ASTRO Junior Faculty Career Research Training Award
  • 2014: KL2 Training Award, OSU Center for Clinical and Translational Sciences (CCTS)
  • 2014: K12 Training Award, First Scholar, OSU-CCC (award declined due to acceptance of KL2)
  • 2014: Co-Lead Organizer, Ohio State University Molecular Biology Cancer Genetics Program Retreat

Society Memberships

  • 2007-Present: American Society for Radiation Oncology (ASTRO)
  • 2008-Present: Radiological Society of North America (RSNA)
  • 2008-Present: American Society of Clinical Oncology (ASCO)
  • 2008-Present: American College of Radiology (ACR)
  • 2010-Present: American Association of Cancer Research (AACR)
  • 2012-Present: Radiation Research Society (RRS)

Committee Memberships

  • 2012-Present: Ohio State University Respiratory-Gated Working Group, Leader
  • 2013-Present: NRG/RTOG Developmental Therapeutics Committee, Gastrointestinal Cancers Liason


  • Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR (1998). Association of CYP3A4 genotype with treatment-related leukemia.  Proc Natl Acad Sci U S A. 95, 13176-81.
  • Megonigal MD, Rappaport EF, Jones DH, Williams TM, Lovett BD, Kelly KM, Lerou PH, Moulton T, Budarf ML, Felix CA. (1998).  t(11;22)(q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes.  Proc Natl Acad Sci U S A. 95, 6413-8.
  • Felix CA, Hosler MR, Slater DJ, Megonigal MD, Lovett BD, Williams TM, Nowell PC, Spinner NB, Owens NL, Hoxie J, Croce CM, Lange BJ, Rappaport EF (1999). Duplicated regions of AF-4 intron 4 at t(4;11) translocation breakpoints.  Mol Diagn. 4, 269-83.

  • Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA (2000). Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.  Proc Natl Acad Sci U S A. 97, 2814-9.

  • Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MP (2003). Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol. 162, 2029-39.

  • Cohen AW, Park DS, Woodman SE, Williams TM, Chandra C, Shirani J, Pereira De Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP (2003). Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 284, C457-74.

  • Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP (2003). Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 285, C222-35.
  • Park DS, Cohen AW, Frank PG, Razani B, Lee H, Williams TM, Chandra M, Shirani J, De Souza AP, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP (2003). Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry42, 15124-31.
  • Williams TM, Cheung M W-C, Park DP, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, and Lisanti MP (2003). Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14, 1027-42.
  • Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP (2003). Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol. 162, 2059-68.
  • Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, Lisanti MP (2004).  Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes. 53, 1261-70.
  • Williams TM, Lisanti MP (2004). The caveolin proteins.  Genome Biol. 5, 214.
  • Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, Scherer PE, Pestell RG, Lisanti MP (2004).  Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem. 279, 24745-56.
  • Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 279, 51630-46.
  • Williams TM, Lisanti MP (2004). The Caveolin genes:  from cell biology to medicine.  Ann Med. 36, 584-95.
  • Williams TM, Lisanti MP (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 288, C494-506.
  • Bonuccelli G, Sotgia F, Frank PG, Williams TM, de Almeida CJ, Tanowitz HB, Scherer PE, Hotchkiss KA, Terman BI, Rollman B, Alileche A, Brojatsch J, Lisanti MP (2005).  ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection.  Am J Physiol Cell Physiol. 288, C1402-10.
  • Capozza F, Combs T, Cohen AW, Cho Y-R, Park S-Y, Williams TM, Brasaemle DL, Jelicks L, Scherer PE, Kim J, Lisanti MP (2005). Caveolin-3 (-/-) knockout mice show increased adiposity and whole-body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle.  Am J Physiol Cell Physiol. 288, C1317-31.
  • Williams TM, Hassan G, Li J, Cohen AW, Medina F, Di Vizio D, Loda M, Lisanti MP (2005).  Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice. J Biol Chem. 280, 25134-45.
  • Iyengar P, Espina V, Williams TM, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE (2005).  Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.  J Clin Invest115, 1163-1176. 
  • Sotgia F, Williams TM, Cohen AW, Minetti C, Pestell RG, Lisanti MP (2005).  Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/beta-catenin signaling.  Cell Cycle. 4 (12), 1808-16.
  • Li J, Hassan GS, Williams TM, Minetti C, Pestell RG, Tanowitz HB, Frank PG, Sotgia F, Lisanti MP (2005).  Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation.  Cell Cycle. 4 (12), 1817-25.
  • Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, Lisanti MP (2006).  Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol. 168 (1), 292-309.
  • Hassan GS, Williams TM, Frank PG, Lisanti MP (2006).  Caveolin-1 Deficient (-/-) Aortic Smooth Muscle Cells Show Cell Autonomous Abnormalities in Proliferation, Migration, and Endothelin-based Signal Transduction.  Am J Physiol Heart Circ Physiol. 2006 Jun; 290 (6):H2393-401.
  • Medina FA, Williams TM, Sotgia F, Tanowitz HB, Lisanti MP (2006).  A novel role for caveolin-1 in B lymphocyte function and the development of thymus-independent immune responses.  Cell Cycle. Aug; 5 (16):1865-71.
  • Medina FA, de Almeida CJ, Dew E, Li J, Bonuccelli G, Williams TM, Cohen AW, Pestell RG, Frank PG, Tanowitz HB, Lisanti MP (2006).  Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection.  Infect Immun. Dec; 74 (12):6665-74.
  • Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP (2006).  Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.  Am J Pathol. Nov;169 (5):1784-801.
  • Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB(2007).   N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation.  Cancer Res67 (7): 3106-16.
  • Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP (2007). Caveolin-1 is Required for the Upregulation of Fatty Acid Synthase (FASN), a Tumor Promoter, During Prostate Cancer Progression.  Cancer Biol Ther. 6 (8): 1263-8.

  • Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams TM, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MP, Freeman MR (2008). Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle, 7 (14): 2257-67.

  • Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG (2011).  Role of cholesterol in the development and progression of breast cancer.  Am J Pathol., 178 (1): 402-12.

  • Williams TM, Moran JM, Hsu SH, Marsh RB, Yanke B, Fraass BA, Pierce LJ (2011).  Contralateral Breast Dose After Whole-Breast Irradiation: An Analysis by Treatment Technique.  IJROBP, 82(5): 2079-85.

  • Schinske KA, Nyati S, Khan AP, Williams TM, Johnson TD, Ross BD, Tomas RP, Rehemtulla A (2011).  A Novel Kinase Inhibitor of FADD Phosphorylation Chemosensitizes though the Inhibition of NF-κB.  Mol Cancer Ther., 10(10): 1807-17.

  • Yao H, Zeng ZZ, Fay KS, Veine DM, Staszewski ED, Morgan M, Wilder-Romans K, Williams TM, Spalding AC, Ben-Josef E, Livant DL (2011).  Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells.  Trans Oncol.  4(5): 282-92.

  • Williams TM, Flecha A, Keller P, Ram A, Karnak D, Galban S, Galban C, Ross B, Lawrence T, Rehemtulla A, Sebolt-Leopold J, (2012).  Co-Targeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer. Mol Cancer Ther., 11(5): 1193-202.
  • Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD (2012).  DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.  PLoS One. 7(4):  e35857.
  • Williams TM, Galban S, Li F, Heist KA, Galban CJ, Lawrence TS, Holland EC, Thomae TL, Chenevert TL, Rehemtulla A, Ross BD. DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases (2013).  Translational Oncol, 6(2):  133-42.
  • Williams TM, Nyati S, Ross BD, Rehemtulla A.  Molecular Imaging of the ATM Kinase Activity (2013).  IJROBP, 86(5): 969-977.
  • Kim EJ, Ben-Josef E, Herman J, Bekaii-Saab T, Dawson L, Griffith K, Francis IR, Greenson J, Simeone DM, Lawrence T, Laheru D, Wolfgang CL, Williams TM, Bloomston, M, Moore M, Wei A, Zalupski MM. A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer (2013). Cancer, 119(15): 2692-700.
  • Ru P, Williams TM, Chakravarti A, Guo D.  Tumor Metabolism of Malignant Gliomas (2013). Cancers (Basel) 5 (4):1469-84.
  • Williams TM, Majithia L, Wang SJ, Thomas CR (2014).  Defining the Role of Adjuvant Therapy:  Cholangiocarcinoma and Gall Bladder Cancer.  Seminars Radiation Oncology (9): 94-104.
  • Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Christopher Ellison E, Bloomston M, Bekaii-Saab T (2014).  Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas.  Ann Surg Oncol Oct 31 [Epub ahead of print]
  • Walston S, Hamstra DA, Oh K, Woods G, Guiou M, Olshefski RS, Chakravarti A, Williams TM (2015).  A multi-institutional experience in pediatric high-grade glioma.  Front Oncol Feb 18;5.
  • Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T (2015).  The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy.  Am J Clin Oncol,  Feb 25.
  • Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA (2015). Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®) by the Pediatric Preclinical Testing Program (PPTP).  Pediatr Blood Cancer, 62 (7): 1214-21.
  • Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Robinson CA, Griffith KA, Chen CS, Ludwig, T, Bekaii-Saab T, Chakravarti A, Williams TM (2015). Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer (In Press, Scientific Reports).
  • Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA (2015). Stromal Caveolin-1 is Associated with Response and Survival in a Phase II trial of nab-Paclitaxel plus Carboplatin for Advanced NSCLC Patients (In Press, Clinical Lung Cancer).
  • Williams TM, Eisbruch AE.  When Should We Include the Ipsilateral Parotid Gland in the Clinical Target Volume in Patients with Mucosal Head and Neck Cancer? (Submitted).
  • Ben-Josef, E, George A, Regine WF, Abrams R, Morgan M, Thomas D, Schaefer PL, DiPetrillo TA, Fromm M, Small W, Narayan S, Winter K, Griffith K, Guha C, Williams TM (2015).  Glycogen Synthase Kinase 3 beta predicts survival in resected adenocarcinoma of the pancreas. (In Revision)